Anti-cancer activity of curcumin loaded nanoparticles in prostate cancer

Biomaterials

Volumn 35, Issue 30, 2014, Pages 8635-8648

  Yallapu, Murali M ^a   Khan, Sheema ^a   Maher, Diane M ^b   Ebeling, Mara C ^b   Sundram, Vasudha ^b   Chauhan, Neeraj ^a   Ganju, Aditya ^a   Balakrishna, Swathi ^a   Gupta, Brij K ^b   Zafar, Nadeem ^c   Jaggi, Meena ^a   Chauhan, Subhash C ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b SANFORD RESEARCH   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Chemoprevention; Curcumin; Nanoparticles; Prostate cancer; Targeted delivery

Indexed keywords

ANTIBODIES; CELL DEATH; CELL PROLIFERATION; MAMMALS; NANOPARTICLES; TUMORS; UROLOGY;

ANTI-APOPTOTIC PROTEIN; CHEMOPREVENTION; CURCUMIN; CYTOSOLIC COMPARTMENTS; POLY LACTIC-CO-GLYCOLIC ACID; PROSTATE CANCERS; TARGETED DELIVERY; THERAPEUTIC POTENTIALS;

DISEASES;

CANCER ANTIBODY; CURCUMIN; IODINE 131; MICRORNA 205; MICRORNA 21; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; POLYGLACTIN; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PSMA ANTIBODY; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BETA CATENIN; MICRORNA; NANOPARTICLE; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER REGRESSION; CANCER TISSUE; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; ISOTOPE LABELING; LNCAP CELL LINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENDOCYTOSIS; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; ULTRASTRUCTURE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; ENDOCYTOSIS; HUMANS; MALE; MICE, NUDE; MICRORNAS; NANOPARTICLES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904738421     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.040     Document Type: Article

References (56)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics. CA Cancer J Clin 2014, 2014(64):9-29.
2. Gianino M.M., Galzerano M., Minniti D., Di N.C., Martin B., Davini O., et al. A comparative costs analysis of brachytherapy and radical retropubic prostatectomy therapies for clinically localized prostate cancer. Int J Technol Assess Health Care 2009, 25:411-414.
3. Snyder C.F., Frick K.D., Blackford A.L., Herbert R.J., Neville B.A., Carducci M.A., et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?. Cancer 2010, 116:5391-5399.
4. Sowery R.D., So A.I., Gleave M.E. Therapeutic options in advanced prostate cancer: present and future. Curr Urol Rep 2007, 8:53-59.
5. Sinha R., Anderson D.E., McDonald S.S., Greenwald P. Cancer risk and diet in india. J Postgrad Med 2003, 49:222-228.
6. Stan S.D., Singh S.V., Brand R.E. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol 2010, 7:347-356.
7. Cimino S., Sortino G., Favilla V., Castelli T., Madonia M., Sansalone S., et al. Polyphenols: key issues involved in chemoprevention of prostate cancer. Oxid Med Cell Longev 2012, 2012:632959.
8. Anand P., Sundaram C., Jhurani S., Kunnumakkara A.B., Aggarwal B.B. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008, 267:133-164.
9. Aggarwal B.B. Prostate cancer and curcumin: add spice to your life. Cancer Biol Ther 2008, 7:1436-1440.
10. Singh R.P., Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006, 13:751-778.
11. Burgos-Moron E., Calderon-Montano J.M., Salvador J., Robles A., Lopez-Lazaro M. The dark side of curcumin. Int J Cancer 2010, 126:1771-1775.
12. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol Pharm 2007, 4:807-818.
13. Epelbaum R., Schaffer M., Vizel B., Badmaev V., Bar-Sela G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer 2010, 62:1137-1141.
14. Ji J.L., Huang X.F., Zhu H.L. Curcumin and its formulations: potential anti-cancer agents. Anticancer Agents Med Chem 2012, 12:210-218.
15. Bansal S.S., Goel M., Aqil F., Vadhanam M.V., Gupta R.C. Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res 2011, 4:1158-1171.
16. Yallapu M.M., Othman S.F., Curtis E.T., Bauer N.A., Chauhan N., Kumar D., et al. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. Int J Nanomedicine 2012, 7:1761-1779.
17. Danhier F., Ansorena E., Silva J.M., Coco R., Le Breton A., Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505-522.
18. Miele E., Spinelli G.P., Tomao F., Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 2009, 4:99-105.
19. Hrkach J., Von Hoff D., Mukkaram Ali M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
20. Yallapu M.M., Gupta B.K., Jaggi M., Chauhan S.C. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 2010, 351:19-29.
21. Perner S., Hofer M.D., Kim R., Shah R.B., Li H., Moller P., et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 2007, 38:696-701.
22. Tricoli J.V., Schoenfeldt M., Conley B.A. Detection of prostate cancer and predicting progression: current and future diagnostic markers. Clin Cancer Res 2004, 10:3943-3953.
23. Kypta R.M., Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat Rev Urol 2012, 9:418-428.
24. Song L.N., Gelmann E.P. Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor. J Biol Chem 2005, 280:37853-37867.
25. Yang X., Chen M.W., Terry S., Vacherot F., Bemis D.L., Capodice J., et al. Complex regulation of human androgen receptor expression by wnt signaling in prostate cancer cells. Oncogene 2006, 25:3436-3444.
26. Yallapu M.M., Maher D.M., Sundram V., Bell M.C., Jaggi M., Chauhan S.C. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res 2010, 3:11.
27. Khan S., Chib R., Shah B.A., Wani Z.A., Dhar N., Mondhe D.M., et al. A cyano analogue of boswellic acid induces crosstalk between p53/puma/bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur J Pharmacol 2011, 660:241-248.
28. Chauhan S.C., Vannatta K., Ebeling M.C., Vinayek N., Watanabe A., Pandey K.K., et al. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. Cancer Res 2009, 69:765-774.
29. Panariti A., Miserocchi G., Rivolta I. The effect of nanoparticle uptake on cellular behavior: disrupting or enabling functions?. Nanotechnol Sci Appl 2012, 5:87-100.
30. Iversen T., Skotland T., Sandig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nanotoday 2011, 6:176-185.
31. Mo L., Hou L., Guo D., Xiao X., Mao P., Yang X. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells. Int J Pharm 2012, 436:815-824.
32. Thomas T.P., Majoros I., Kotlyar A., Mullen D., Holl M.M., Baker J.R. Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations. Biomacromolecules 2009, 10:3207-3214.
33. Tahara Y., Nakamura M., Yang M., Zhang M., Iijima S., Yudasaka M. Lysosomal membrane destabilization induced by high accumulation of single-walled carbon nanohorns in murine macrophage RAW 264.7. Biomaterials 2012, 33:2762-2769.
34. Mukerjee A., Vishwanatha J.K. Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 2009, 29:3867-3875.
35. Aoki H., Takada Y., Kondo S., Sawaya R., Aggarwal B.B., Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007, 72:29-39.
36. Yallapu M.M., Dobberpuhl M.R., Maher D.M., Jaggi M., Chauhan S.C. Design of curcumin loaded cellulose nanoparticles for prostate cancer. Curr Drug Metab 2012, 13:120-128.
37. Lane J.D., Allan V.J., Woodman P.G. Active relocation of chromatin and endoplasmic reticulum into blebs in late apoptotic cells. J Cell Sci 2005, 118:4059-4071.
38. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
39. Abdulghani J., Gu L., Dagvadorj A., Lutz J., Leiby B., Bonuccelli G., et al. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 2008, 172:1717-1728.
40. Shukla S., Maclennan G.T., Hartman D.J., Fu P., Resnick M.I., Gupta S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 2007, 121:1424-1432.
41. Wang G., Wang J., Sadar M.D. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008, 68:9918-9927.
42. Sundram V., Chauhan S.C., Ebeling M., Jaggi M. Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1. PloS One 2012, 7:e35368.
43. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
44. Sheth S., Jajoo S., Kaur T., Mukherjea D., Sheehan K., Rybak L.P., et al. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PloS One 2012, 7:e51655.
45. Gandellini P., Folini M., Longoni N., Pennati M., Binda M., Colecchia M., et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res 2009, 69:2287-2295.
46. Teiten M.H., Gaascht F., Eifes S., Dicato M., Diederich M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr 2010, 5:61-74.
47. Kunnumakkara A.B., Anand P., Aggarwal B.B. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008, 269:199-225.
48. Shekhar C. Lean and mean: nanoparticle-based delivery improves performance of cancer drugs. Chem Biol 2009, 16:349-350.
49. Yallapu M.M., Othman S.F., Curtis E.T., Gupta B.K., Jaggi M., Chauhan S.C. Multi-functional magnetic nanoparticles for magnetic resonance imaging and cancer therapy. Biomaterials 2011, 32:1890-1905.
50. Algeciras-Schimnich A., Barnhart B.C., Peter M.E. Apoptosis dependent and independent functions of caspases. Caspases-their role in cell death and cell survival 2002, Kluwer Academic/Plenum Publishers, New York, USA. L. Marek, H. Walczak (Eds.).
51. Mak P., Jaggi M., Syed V., Chauhan S.C., Hassan S., Biswas H., et al. Protein kinase D1 (PKD1) influences androgen receptor (AR) function in prostate cancer cells. Biochem Biophys Res Commun 2008, 373:618-623.
52. Jaggi M., Chauhan S.C., Du C., Balaji K.C. Bryostatin 1 modulates beta-catenin subcellular localization and transcription activity through protein kinase D1 activation. Mol Cancer Ther 2008, 7:2703-2712.
53. Ravindran J., Prasad S., Aggarwal B.B. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?. AAPS J 2009, 11:495-510.
54. Merika E.E., Syrigos K.N., Saif M.W. Desmoplasia in pancreatic cancer. Can we fight it?. Gastroenterol Res Pract 2012, 2012:781765.
55. Ungaro F., Conte C., Ostacolo L., Maglio G., Barbieri A., Arra C., et al. Core-shell biodegradable nanoassemblies for the passive targeting of docetaxel: features, antiproliferative activity and in vivo toxicity. Nanomedicine 2012, 8:637-646.
56. Yallapu M.M., Ebeling M.C., Chauhan N., Jaggi M., Chauhan S.C. Interaction of curcumin nanoformulations with human plasma proteins and erythrocytes. Int J Nanomedicine 2011, 6:2779-2790.